Novo Nordisk A/S
NYSE:NVO · New York Stock Exchange
-$0.48 today
Vol 7.98M · Avg 16.05M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NYSE:NVO · Revenue to Net Income
Key Ratios
Analysis
$327.8B of revenue converted into $122.0B of net income for the selected period. Gross margin is 81.6% and net margin is 36.3%, showing how much revenue survives after costs and taxes. EPS is $27.41, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $309.1B +6.4% | $290.4B +25.0% | $232.3B +31.3% | $177.0B +25.7% | $140.8B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $58.8B +32.0% | $44.5B +24.5% | $35.8B +25.7% | $28.4B +20.2% | $23.7B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $250.3B +1.8% | $245.9B +25.1% | $196.5B +32.3% | $148.5B +26.8% | $117.1B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 81.0% -3.7pp | 84.7% +0.1pp | 84.6% +0.7pp | 83.9% +0.7pp | 83.2% | 9.8% | 28.9% | 38.3% |
| Research & Development | $52.0B +8.3% | $48.1B +48.1% | $32.4B +34.9% | $24.0B +35.3% | $17.8B | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $70.3B +4.3% | $67.4B +9.4% | $61.6B +21.5% | $50.7B +23.4% | $41.1B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $122.6B +4.3% | $117.5B +25.1% | $93.9B +27.4% | $73.7B +26.0% | $58.5B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $22.0B +15.0% | $19.1B +103.0% | $9.4B +27.9% | $7.4B +22.2% | $6.0B | $374.2M | $1.2B | $631.8M |
| EBITDA | $156.7B +5.9% | $147.9B +29.1% | $114.6B +49.3% | $76.8B +17.4% | $65.4B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 50.7% -0.2pp | 50.9% +1.6pp | 49.4% +6.0pp | 43.4% -3.0pp | 46.4% | 5.6% | 46.3% | 42.0% |
| Operating Income | $127.7B -0.5% | $128.3B +25.1% | $102.6B +37.1% | $74.8B +27.6% | $58.6B | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 41.3% -2.9pp | 44.2% +0.0pp | 44.2% +1.9pp | 42.3% +0.6pp | 41.7% | 16.6% | 24.1% | 22.0% |
| Interest Income | $1.3B -31.0% | $1.8B +71.9% | $1.1B +347.3% | $239.0M +3.5% | $231.0M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $4.2B +156.5% | $1.6B +202.6% | $542.0M +43.4% | $378.0M +30.8% | $289.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $2.9B +351.0% | -$1.1B -154.7% | $2.1B +136.5% | -$5.7B -1418.1% | $436.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $130.5B +2.6% | $127.2B +21.5% | $104.7B +51.6% | $69.1B +16.9% | $59.1B | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 42.2% -1.6pp | 43.8% -1.3pp | 45.1% +6.0pp | 39.0% -2.9pp | 42.0% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $28.1B +7.3% | $26.2B +24.8% | $21.0B +55.1% | $13.5B +19.6% | $11.3B | $1.3B | -$1.6B | $745.2M |
| Net Income | $102.4B +1.4% | $101.0B +20.7% | $83.7B +50.7% | $55.5B +16.3% | $47.8B | $4.9B | $4.8B | $4.7B |
| Net Margin | 33.1% -1.6pp | 34.8% -1.3pp | 36.0% +4.7pp | 31.4% -2.5pp | 33.9% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $23 +1.7% | $23 +21.4% | $19 +52.3% | $12 +17.9% | $10 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $23 +1.8% | $23 +21.5% | $19 +52.4% | $12 +17.8% | $10 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $4.4B -0.1% | $4.5B -0.6% | $4.5B -1.1% | $4.5B -1.4% | $4.6B | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $4.4B -0.3% | $4.5B -0.7% | $4.5B -1.1% | $4.5B -1.3% | $4.6B | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Merck & Co., Inc.
NYSE:MRK
$281.73B
Novartis AG
NYSE:NVS
$281.18B
AstraZeneca PLC
NYSE:AZN
$271.11B
Amgen Inc.
NASDAQ:AMGN
$180.68B
Thermo Fisher Scientific Inc.
NYSE:TMO
$173.24B
Abbott Laboratories
NYSE:ABT
$153.30B
Gilead Sciences, Inc.
NASDAQ:GILD
$152.54B
Pfizer Inc.
NYSE:PFE
$143.68B
GSK plc
NYSE:GSK
$101.90B
Sanofi
NASDAQ:SNY
$101.56B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does NVO generate?
Novo Nordisk A/S (NVO) reported $309.06B of revenue in fiscal 2025.
Is NVO profitable?
Novo Nordisk A/S (NVO) reported $102.43B of net income, with a net margin of 33.1%.
Explore More
Continue the stock analysis
Jump to another research area for this company.